Seres Therapeutics Inc (MCRB)

$0.82

Market is closed - opens 7 PM, 04 Nov 2024

Performance

  • $0.79
    $0.83
    $0.82
    downward going graph

    3.61%

    Downside

    Day's Volatility :4.19%

    Upside

    0.61%

    downward going graph
  • $0.54
    $2.05
    $0.82
    downward going graph

    34.15%

    Downside

    52 Weeks Volatility :73.66%

    Upside

    60.0%

    downward going graph

Returns

PeriodSeres Therapeutics IncSector (Health Care)Index (Russel 2000)
3 Months
-34.94%
-2.8%
0.0%
6 Months
-24.09%
4.5%
0.0%
1 Year
-43.07%
17.7%
0.0%
3 Years
-87.27%
9.9%
-25.0%

Highlights

Market Capitalization
133.2M
Book Value
-$0.57
Earnings Per Share (EPS)
-1.19
PEG Ratio
-0.11
Wall Street Target Price
3.89
Profit Margin
0.0%
Operating Margin TTM
-42211.23%
Return On Assets TTM
-27.1%
Return On Equity TTM
-538.57%
Revenue TTM
374.0K
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
-93.4%
Gross Profit TTM
-165.8M
EBITDA
-151.6M
Diluted Eps TTM
-1.19
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.94
EPS Estimate Next Year
-0.55
EPS Estimate Current Quarter
-0.27
EPS Estimate Next Quarter
-0.26

Analyst Recommendation

Buy
    76%Buy
    15%Hold
    7%Sell
Based on 13 Wall street analysts offering stock ratings for Seres Therapeutics Inc(by analysts ranked 0 to 5 stars)
Based on 13 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
10
10
10
Hold
2
2
2
Sell
1
1
1

Analyst Forecast

What analysts predicted

Upside of 374.39%

Current $0.82
Target $3.89

Technicals Summary

Sell

Neutral

Buy

Seres Therapeutics Inc is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Seres Therapeutics Inc
Seres Therapeutics Inc
-14.72%
-24.09%
-43.07%
-87.27%
-77.78%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-19.94%
-7.23%
5.93%
31.14%
169.97%
Biontech Se
Biontech Se
-5.69%
25.74%
21.03%
-58.77%
584.62%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
-3.43%
77.77%
69.8%
60.25%
192.92%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
1.32%
18.36%
28.88%
156.73%
136.88%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Seres Therapeutics Inc
Seres Therapeutics Inc
NA
NA
-0.11
-0.94
-5.39
-0.27
NA
-0.57
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
24.57
24.57
1.27
44.77
0.17
0.08
NA
261.41
Biontech Se
Biontech Se
160.8
NA
0.04
-2.76
-0.03
-0.02
NA
80.22
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-2.39
-15.01
0.02
NA
-0.02
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
0.57
0.16
-0.03
0.13
NA
57.26
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Seres Therapeutics Inc
Seres Therapeutics Inc
Buy
$133.2M
-77.78%
NA
0.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$102.2B
169.97%
24.57
32.04%
Biontech Se
Biontech Se
Buy
$27.1B
584.62%
160.8
-18.75%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$36.5B
192.92%
NA
-3.11%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$122.6B
136.88%
32.84
-4.74%

Insights on Seres Therapeutics Inc

  • Decreasing Revenue

    Revenue is down for the last 3 quarters, 126.47M → 64.0K (in $), with an average decrease of 89.6% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 4 quarters, -47.85M → -32.86M (in $), with an average increase of 13.6% per quarter

  • Vs ALNY

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 69.8% return, outperforming this stock by 112.9%

  • Vs VRTX

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 60.2% return, outperforming this stock by 147.5%

Institutional Holdings

  • Flagship Ventures Management, Inc.

    13.58%
  • FMR Inc

    13.35%
  • Vanguard Group Inc

    3.69%
  • TANG CAPITAL MANAGEMENT LLC

    1.41%
  • Millennium Management LLC

    1.04%
  • BlackRock Inc

    1.04%

Company Information

seres therapeutics is a clinical stage biotherapeutic company focused on discovering and developing ecobiotic™ therapeutic products, novel drugs to treat important diseases by targeting the underlying biology of the human microbiome. founded by flagship venturelabs, seres is pioneering the first therapeutics that catalyze a shift to health by augmenting the biology of the microbiome. current candidates span infectious, metabolic, and inflammatory diseases. for more information, please visit http://serestherapeutics.com/.

Organization
Seres Therapeutics Inc
Employees
233
CEO
Mr. Eric D. Shaff M.B.A.
Industry
Health Technology

FAQs